2022/05/12 ALA-1000 祕魯核准專利在案
在〈2022/05/12 ALA-1000 祕魯核准專利在案〉中留言功能已關閉
2022 年 5 月 12 日
Single-ascending-dose (SAD) study successfully demonstrated the safety, tolerability, and sustained release profile at least 3 months resulting from ALA-1000 injection in patients with opioid dependence.